Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients with Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

INCLUSION CRITERIA - ALL SUBJECTS : • Males or females ≥ 50 years of age • Body weight ≥ 45 and ≤ 110 kg • Willing to adhere to calcium and vitamin D supplementation requirements • Females must be of non-reproductive potential INCLUSION CRITERIA - SUBJECTS WITH RENAL IMPAIRMENT (GROUPS 1 AND 2): • Group 1 - Stage 4 RI (estimated glomerular filtration rate (eGFR) 15-29 mL/min/1.73 m²) • Group 2 – End stage renal disease requiring hemodialysis INCLUSION CRITERIA - HEALTHY SUBJECTS (GROUP 3): • Renal function defined as an estimated glomerular filtration rate (eGFR) ≥ 80 mL/min/1.73 m² EXCLUSION CRITERIA - ALL SUBJECTS: • History of metabolic or bone disease (except for metabolic bone disease in renal impairment (RI) subjects) • History of osteoporosis, vertebral fracture, or fragility fracture of the wrist, humerus, hip, or pelvis after age 50 • Recent bone fracture • Vitamin D insufficiency • Hypocalcemia or hypercalcemia • Hypomagnesemia • Hypophosphatemia • Untreated hyper- or hypothyroidism • Females with a positive pregnancy test • Males with pregnant partners • Females who are lactating/breastfeeding or plan to breastfeed on study and for 3 months after receiving the dose of study drug • History of spinal stenosis • History of facial nerve paralysis • Positive for human immunodeficiency virus (HIV) antibodies • Positive for hepatitis B surface antigen or detectable hepatitis C • Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical, or breast ductal carcinoma in situ) within 5 years before screening • History of solid organ or bone marrow transplants EXCLUSION CRITERIA - HEALTHY SUBJECTS (GROUP 3) • Current hyper- or hypoparathyroidism